期刊
AMERICAN JOURNAL OF GASTROENTEROLOGY
卷 104, 期 6, 页码 1475-1482出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ajg.2009.128
关键词
-
资金
- Manitoba Health Research Council
- Canadian Institutes of Health Research [152348]
OBJECTIVES: The use of the common antidepressant class of serotonin-specific reuptake inhibitors (SSRIs) is associated with an increased risk of upper gastrointestinal bleeding (UGIB). Proton pump inhibitors (PPIs) have been demonstrated to reduce the risk of gastrointestinal bleeding secondary to other risk factors, most notably non-steroidal anti-inflammatory drug (NSAID) use. The role for PPIs in chronic SSRI users without other risk factors remains uncharacterized. METHODS: We used the Manitoba Population Health Research Data Repository to perform a population based matched case-control analysis. All patients admitted to the hospital with a primary diagnosis of UGIB were matched to non-bleeding controls. We used conditional regression analysis to determine the risk of UGIB associated with SSRI use, and the risk reduction associated with concomitant PPI use, both for users and non-users of NSAIDs. RESULTS: SSRI use was associated with a modest increase in the risk of UGIB (odds ratio (OR), 1.43; 95 % confidence interval (CI), 1.09-1.89). The addition of an SSRI to NSAID therapy did not significantly increase the risk of UGIB (OR, 1.20; 95 % CI, 0.78-1.92) over use of an NSAID alone. PPI cotherapy significantly reduced the risk of SSRI-related UGIB (OR, 0.39; 95 % CI, 0.16-0.94). CONCLUSIONS: SSRI use is associated with a modestly increased risk of UGIB, which may be significantly reduced with PPI cotherapy. SSRI use is not a major risk factor for NSAID-related UGIB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据